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Patients with renal impairment progressively lose the ability to excrete phosphorus. Decreased glomerular filtration of phosphorus
is initially compensated by decreased tubular reabsorption, regulated by PTH and FGF23, maintaining normal serum phosphorus
concentrations. There is a close relationship between protein and phosphorus intake. In chronic renal disease, a low dietary protein
content slows the progression of kidney disease, especially in patients with proteinuria and decreases the supply of phosphorus,
which has been directly related with progression of kidney disease and with patient survival. However, not all animal proteins
and vegetables have the same proportion of phosphorus in their composition. Adequate labeling of food requires showing the
phosphorus-to-protein ratio. The diet in patients with advanced-stage CKD has been controversial, because a diet with too low
protein content can favor malnutrition and increase morbidity and mortality. Phosphorus binders lower serum phosphorus and
also FGF23 levels, without decreasing diet protein content. But the interaction between intestinal dysbacteriosis in dialysis patients,
phosphate binder eﬃcacy, and patient tolerance to the binder could reduce their eﬃciency.
1. Introduction
Daily phosphorus ingestion is approximately 1200mg, of
which 950mg are absorbed. Around 29% of body phos-
phorus is located in bone, and less than 1% is in the
blood, which is the phosphorus that is quantified in clinical
practice. Most phosphorus (70%) is located intracellularly
and is interchangeable. Phosphorus is removed by two
systems, the gastrointestinal tract, (150mg/day) and the
urine (800mg/day) [1]. Ingestion of phosphorus by an
individual with normal renal function results in immedi-
ate phosphaturia probably mediated by phosphatonins of
intestinal origin [2]. A positive phosphorus balance recruits
other phosphatonins. The first one, faster and transient, is
parathyroid hormone (PTH) and the second one, slower and
lasting, is Fibroblast Growth Factor 23 (FGF23).
Patients with renal impairment progressively lose the
ability to excrete phosphorus. Decreased glomerular filtra-
tion of phosphorus is initially compensated by decreased
tubular reabsorption regulated by PTH and FGF 23. This
compensation leads to a normal urinary excretion of
phosphorus in 24 h and in maintenance of normal serum
phosphorus [3]. However, the adequacy of 24 h urinary
phosphorus excretion is diﬃcult to interpret, since we do
not know the phosphorus ingested, and, as renal function
deteriorates, a positive phosphorus balance results.
FGF23 is a 251 amino acid phosphatonin, which pro-
motes phosphaturia by decreasing phosphorus reabsorption
through inhibition of Na/P cotransporter type II activity in
proximal tubules and by decreasing phosphorus absorption
in the gut by inhibiting generation of active vitamin D in
proximal tubules through inhibition of renal 1 alpha hydrox-
ylase. Reduced active vitamin D facilitates PTH secretion,
which further promotes renal phosphorus excretion [4–6].
FGF23 is released by bone generating the concept of an osteo-
renal axis for phosphorus balance control that has changed
traditional paradigms [4].
2. Protein Intake and Phosphorus
There is a close relationship between protein and phosphorus
intake [7]. Proteins are rich in phosphorus so most of the
scientific societies recommend reducing protein intake from
early stages in patients with chronic renal failure, to reduce
the input of phosphorus. One gram of protein has 13–
15mg of phosphorus of which 30–70% is absorbed through
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the intestine. Thus, an intake of 90 g of proteins a day
results in absorption of 600–700mg of phosphorus daily.
In hemodialysis the net positive phosphorus balance in 48
hours is 1200–1400mg/day, of which dialysis only removes
500–600mg/session. Thus, there are two good reasons to
restrict protein intake in chronic renal disease. On one
side, a low dietary protein content slows the progression of
kidney disease, especially in patients with proteinuria [8].
In addition,a protein-restricted diet decreases the supply of
phosphorus, which has been directly related with progression
of kidney disease and with patient survival. A restricted
protein diet has additional advantages (Table 1). In advanced
chronic kidney disease (CKD) most guidelines recommend
a diet containing 0.6 to 0.8 g protein/kg/day based on meta-
analysis demonstrating its eﬃcacy [9]. This restriction is safe
nutritionally and metabolically [10].
After initiating dialysis the dietary protein intake should
be increased. Hemodialysis patients with higher protein
intake have improved survival, despite higher phosphorus
intake [11]. In a post hoc analysis of the HEMO study
patients without dietary protein restriction have a better
survival than those eating a protein-restricted diet [12].
However, a high protein intake is associated with a high
intake of phosphorus and the latter is associated with
increased cardiovascular mortality. This relationship holds
even when adjusted for serum phosphorus, type and dose of
phosphorus binders, and protein and energy intake [13]. For
this reason an adequate protein intake should be associated
with a restriction of dietary phosphorus.
The Food and Nutrition Board of the Institute of
Medicine recommends a diet with 700mg/day of phosphorus
in healthy people, and 1250mg/day in children and pregnant
women [14]. However, a lower intake is recommended in the
renal patient to reduce. The same recommendations advise
restricting food additives containing phosphorus.
3. Phosphorus Absorption and Protein of
Different Origins
Phosphorus in foods is found in diﬀerent forms. Organic
phosphorus associates with proteins has a low absorption.
By contrast absorption of inorganic phosphorus found in
additives and preservatives is very high, above 90%. A large
amount of phosphate are added to foods as preservatives
as well as from common beverages such cola, with a high
phosphate content [15]. However, organic phosphorus from
plant protein has a lower absorption than phosphorus from
animal protein, ranging from 40 to 50%. The reason is
that phosphorus from plants is in the form of phytates and
mammals lack phytases. Phosphorus in animal protein is in
the form of organic phosphate, which is readily hydrolyzed
and absorbed [16].
In rats with slowly progressive renal failure fed a casein-
based or a grain-based protein diet, both of which with
equivalent total phosphorus contents had the same serum
phosphorous levels. However, the casein-fed animals had
increased urinary phosphorus excretion and elevated serum
FGF23 compared to the grain-fed rats [17].
Table 1: Consequences of dietary protein restriction in advanced
chronic kidney disease.
Reduces proteinuria.
Improves lipid control
Reduces uremic toxins and acids
Reduces oxidative stress
Improves insulin resistance
Reduces phosphorus load
In a crossover trial 11 patients with CKD stages 3-
4 ingested a diet with animal or vegetable protein for 7
days. Animal protein intake increased serum phosphorus and
FGF23 more than vegetable protein intake [18]. The simple
recommendation is to reduce preservatives and additives in
the first place, favor foods rich in vegetables, reduce meat,
and avoid convenience foods.
However, not all animal proteins and vegetables have the
same proportion of phosphorus in their composition. There
are tables and graphics depicting the amount of phosphorus
contained in various foods [19]. Adequate labeling of food
requires showing the ratio of phosphorus (in mg) to protein
(in grams). The ratio ranges from <10 to >65mg/g. Cheese
and soft drinks have a high ratio. This ratio is recommended
by KDOQI guidelines and has several advantages [19].
(a) It is independent of the portion of food served.
(b) It simultaneously represents the contribution of
phosphorus, and protein.
(c) It draws attention to the phosphorus-rich foods,
especially soft drinks and additives and are not
proteins.
However, this ratio does not provide information on
the bioavailability of phosphorus from diﬀerent sources.
Patients with CKD should be prescribed a low phosphorus,
low inorganic phosphorus and low phosphorus/protein ratio
diet, and with a proper protein content to improve the
attractiveness of food.
The Mediterranean diet, until recently widespread in
Spain, has a low phosphorous content and has been shown to
reduce plasma homocysteine, serum phosphorus, microal-
buminuria, and cardiovascular risk [20]. Food additives and
preservatives are rich in phosphorus [21]. Additives account
for about 1000mg/day of phosphorus on average in the
American diet. This amount is important in patients on
hemodialysis [22]. Cheese and soft drinks have a high con-
tent of phosphoric acid, in addition to a high phosphorus-
to-protein ratio [23].
Phosphorus intake is now a hallmark of poor quality
food. Individuals with lower socioeconomic status and a
lower income have higher serum phosphorus possibly due
to the abuse of preprepared meals and fast food containing
additives [24].
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4. Low-Protein Diet andMalnutrition
The diet in patients with advanced-stage CKD has been
controversial throughout the history of Nephrology. CKD
is associated with protein calorie malnutrition [25]. A diet
with a too low-protein content can favor malnutrition and
increase morbidity andmortality [7]. However a low-protein
diet can slow the progression of renal disease. While nor-
moproteic or high-protein diet may increase uremic symp-
toms and hyperphosphatemia. A delicate balance should
be sought. A low-protein diet in CKD has the following
potential advantages (Table 1): decreases uremic symptoms
[11], improves phosphorus control [11], delays initiation of
dialysis [9], does not increase the risk of proteinmalnutrition
if accompanied by essential amino acid supplement [26],
does not increase mortality in patients with low-protein diet
after starting dialysis [27], and protects against oxidative
stress which may aggravate progression of CKD [28].
In dialysis, protein intake should not be restricted despite
a higher intake of phosphorus, since the risk of protein
malnutrition and mortality exceeds that of hyperphos-
phatemia [11]. When dialysis patients are prescribed a low-
protein intake, actual protein intake is frequently lower than
expected, possibly because of the diﬃculty in implementing
the diet. Thus, a recommended intake of 0.3–0.6 g/kg/day
protein is estimated to result in an actual intake of 0.48–
0.84 g/kg/day [26, 29]. Implementation of a low-protein diet
requires a dedicated staﬀ, with nurses, dietitians, and a
close monitoring by nephrologists. However, in hemodialysis
patients net phosphorus balance on a normoproteic diet
is positive even after deducting the phosphorus removed
during the dialysis session. Hemodialysis removes 800mg
phosphorus/session (2400mg/week). Thus, a protein intake
of 1 g/kg BW/day as recommended will result in an estimated
weekly net balance of phosphorus of 2000mg.
Savica el al. suggest to the patients undergoing periodic
HD that they must ingest a quantity of protein of 1,2–
1,4 gr per Kg of body weight in the day and in other hand
that they must ingest a quantity of phosphate no more
than 800mg per day. So 1,2–1,4 gr of protein correspond to
1.450mg–1600mg of phosphate and 800mg of phosphate
correspond to 0.6mg per Kg b.w. per day. If the patients
follow the suggestion to ingest no more 800mg of phosphate
in the day they are at high risk for malnutrition. In fact
both dialysis treatment and phosphate binders are unable to
remove the phosphate ingested [15]. We report that 74% of
CKD pts ingest beverages and if we considere this evidence
we can calculate a weekly net positive balance of phosphate
of about 2.800mg. This weekly quantity of phosphate is very
dangerous for calcification in CKD pts [30].
The association between low-protein intake and inc-
reased mortality in dialysis patients suggests that alternative
methods are needed to reduce phosphorus absorption, since
high phosphorus is associated with mortality. There are
two main alternatives. One is the use of specific nutritional
supplements high in energy and protein content, but low
in phosphorus. This diet allows maintaining an adequate
nutritional status, without altering the serum phosphorus,
and without need for higher phosphorus binders [31]. The
second alternative is nutritional education of the patient.
This includes greater attention to additives and preservatives,
to the contribution of phosphorus from diﬀerent protein
foods, so that the diet is based on low phosphorus/protein
ratio ingredients, as well as the proper and early use of
phosphorus binders [11].
5. Phosphorus Binders
In a major retrospective study patients treated with phos-
phorus binders before entering dialysis and phosphate above
3.7mg/dL, had a better long-term survival than those in
whom binders were initiated after initiation of dialysis.
Similar results were obtained when binder use in the first 90
days of dialysis was compared with later initiation of binders
[32]. The authors speculated that the observation might
be explained by modulation of direct eﬀect of phosphorus
or compensatory mechanisms such as FGF23 on patient
survival [33]. However, this reduction in mortality was not
observed in incident dialysis patients treated with calcium-
containing binders, either calcium acetate or calcium car-
bonate [34]. Phosphorus binders lower serum phosphorus
and also lower FGF23 levels. Indeed in early CKD binders
may result in reduced FGF23 levels in the absence of changes
in serum phosphorus [35].
The purpose of therapy with usual phosphate binders
is either to limit the absorption of dietary phosphorous
intake and to maintain phosphatemia in normal range.
Mostly of them act by binding phosphate in gut and
eliminating it in the stool. Authors have observed that the
salivary phosphorous ratio in hemodialysis patients is more
than doubled compared with healthy controls [36, 37].
Same authors have demonstrated that salivary phosphate
binders, like chitosan-loaded chewing gum, reduced serum
phosphate [38].
6. Different Efficacy and Tolerance between
Captors: Binding to Bile Salts
There are diﬀerent phosphorus binders for clinical use,
which have diﬀerent binding power and side eﬀects. In
addition, the binding power and side eﬀects may diﬀer
between individuals and impact on eﬃcacy [39]. The main
side eﬀects relate to digestive tolerance in around 15–20% of
patients. [40, 41]. In case of intolerance, modification of the
prescribed binders may reduce the side eﬀects and decrease
the absorption of phosphorus. Lanthanum carbonate has
been successfully used in controlling hyperphosphatemia in
patients with intolerance to other binders [42].
To better understand the causes of reduced eﬃciency and
digestive intolerance, we must understand the peculiarities
of the digestive tract in uremic patients. CKD patients
frequently have intestinal dysbacteriosis, which may be
multifactorial [43] (Table 2).
Disbacteriosis promotes the release of products of bac-
terial metabolism that may enter the blood and originate
uremic toxins such as phenols, indoles, and amines. Uremic
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Table 2: Causes of CKD patients intestinal dysbacteriosis.
Dialysis patients eat less fiber than healthy individuals, in part
because dietary restrictions that includes the reduction of fruit
and vegetables to avoid an overload of potassium.
Uremia results in intestinal acidification.
Certain drugs, such as antibiotics and phosphate binders alter
the intestinal flora.
Bowel dysfunction may cause constipation or increased
intestinal transit time.
The metabolism and absorption of proteins is altered and this
may lead to malnutrition.
toxins may contribute to an increased risk of cardiovascular
and bone disease.
Uremic patients may have a poor digestion and malab-
sorption of protein, carbohydrates, and fats [44]. Potential
causes are bacterial overgrowth or disorders of the exocrine
pancreas or biliary function. Indeed, uremia is associated
with high plasma levels of peptides such as secretin, pancre-
atic secretagogues and gastrin, and an abnormal composition
of pancreatic secretion, including low bicarbonate and
amylase levels.
Some phosphate binders bind to bile salts. Ten out of 49
dialysis patients studied had bacterial overgrowth as assessed
by the lactulose test, and this was associated with dyspepsia
[44]. Sevelamer exacerbated dyspepsia, but supplementation
of oral pancreatic enzymes improved symptoms and the
phosphate binder eﬀectiveness. This highlights the inter-
action between intestinal dysbacteriosis, phosphate binder
eﬃcacy and patient tolerance to the binder.
Phosphorus binders binding to bile salts may interfere
with soluble molecules that require biliary salts for absorp-
tion. In this sense sevelamer binding to bile salts results
in reduced cholesterol absorption and lower serum LDL-
cholesterol and in reduced vitamin D absorption [45].
7. Conclusions
Phosphate overload and hyperphosphatemia have emerged
as risk factors for vascular calcification, cardiovascular
mortality, left ventricular hypertrophym and progression of
chronic kidney disease. Normoprotein or high-protein diet
may increase uremic symptoms and hyperphosphatemia, but
low protein intake and increasedmortality in dialysis patients
suggests that alternative methods are needed to reduce
phosphorus absorption. An adequate nutritional status
includes greater attention to additives and preservatives, to
the contribution of phosphorus from diﬀerent protein foods,
a diet based on low phosphorus/protein ratio ingredients as
well as the proper and early use of phosphorus binders.
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